DAP1

General Information


DRACP ID  DRACP01037

Peptide Name   DAP1

Sequence  LWKRWVGVWRKWL

Sequence Length  13

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
A549 Lung adenocarcinoma Carcinoma IC50=11.9 µM MTT assay 48h 1
OVCAR-3 High grade ovarian serous adenocarcinoma Carcinoma IC50=8.6 µM MTT assay 48h 1
NCI/ADR-RES High grade ovarian serous adenocarcinoma Carcinoma IC50=14.0 µM MTT assay 48h 1
T24 Bladder carcinoma Carcinoma IC50=15.3 µM MTT assay 48h 1

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  HUVEC: IC50=19.5 μM; NL20: IC50=19.0 μM

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antitumor; Antimicrobial



Structure Information


PDB ID  Not available

Predicted Structure  DRACP01037

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Amidation

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C92H133N25O14

Absent amino acids  ACDEFHIMNPQSTY

Common amino acids  W

Mass  202745

Pl  12.53

Basic residues  4

Acidic residues  0

Hydrophobic residues  8

Net charge  4

Boman Index  -1276

Hydrophobicity  -36.92

Aliphatic Index  104.62

Half Life 
  Mammalian: 1.3 hour
  Yeast: 3 min
  E.coli: 2 min

Extinction Coefficient cystines  22000

Absorbance 280nm  1833.33

Polar residues  1

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 33184577

Title  Re-engineering Antimicrobial Peptides into Oncolytics Targeting Drug-Resistant Ovarian Cancers

Doi 10.1007/s12195-020-00626-z

Year  2020

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.